



NDA 20380/S-013

**SUPPLEMENT APPROVAL**

Galderma Laboratories, L.P.  
Attention: S. Chase Edwards  
Senior Manager, Regulatory Affairs  
14501 North Freeway  
Firth Worth, TX 76177

Dear Mr. Edwards:

Please refer to your Supplemental New Drug Application (sNDA) dated September 22, 2017, received September 25, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Differin Gel (adapalene), 0.1%.

This Prior Approval sNDA provides for changes to the graphics and text located on the secondary packaging (carton) configurations.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the enclosed labeling as outlined in the below table and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<b>Submitted Labeling</b>	<b>Date Submitted</b>
2 g blister card	September 25, 2017
15 g carton with “NEW LOOK SAME FORMULA” flag	March 7, 2018
15 g carton standard	March 7, 2018
45 g carton with “NEW LOOK SAME FORMULA” flag	March 7, 2018
45 g carton standard	March 7, 2018

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 020380/S-013.**” Approval of this submission by FDA is not required before the labeling is used.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lara Akinsanya, Regulatory Project Manager, at (301) 796-9634.

Sincerely,

*{See appended electronic signature page}*

Theresa Michele, MD  
Director  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURES:

Carton Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

THERESA M MICHELE  
03/23/2018